New studies highlight that while persistent SARS-CoV-2 infections can evolve rapidly within individuals, they rarely spread onward. Meanwhile, the 2024–2025 COVID-19 vaccine reduced mortality by 64% among...
In this roundup, experts outline diverging pediatric COVID vaccine recommendations, midlife peaks in long COVID risk, new findings on abnormal uterine bleeding and cycle-related symptoms in long COVID, and...
In a phase 1 trial, a single injection of an mRNA RSV vaccine boosted neutralizing antibody levels in seropositive children and was well tolerated, with no serious adverse events or study discontinuations...
A multilevel intervention improved human papillomavirus vaccine initiation and completion among most children aged 11 to 12 years, though the effect was limited for those living in under-resourced settings,...
New research shows stalled childhood vaccine progress, elevated heart risks linked to COVID-19 vaccines in young men, and rising gastrointestinal disorders during the pandemic.
A national analysis of county-level measles-mumps-rubella vaccination rates from 2017 to 2024 shows a significant decline following the COVID-19 pandemic, with geographic variation and implications for...
New research explores long COVID risks in children, ACIP's expanded RSV vaccine use, U.S. disease resurgence under falling immunization, and long COVID’s burden on health care workers.
A phase 3 study found that the 20-valent pneumococcal conjugate vaccine (PCV20) elicited strong immune responses across all 20 serotypes and had a safety profile comparable with PCV13.
Researchers aimed to describe the most common symptoms of long COVID and the progression of symptoms over time. They presented their findings at IDWeek 2023 in Boston, Massachusetts.
